Abstract: A method and device for publishing at least one message and a storage medium is provided. The method includes the following steps. A first message published by a first session account in a first session of an instant messaging client is acquired, and session accounts participating in the first session include at least three session accounts containing the first session account, and the first message is used for allowing reply information of at least one reply of at least one session account participating in the first session to the first message to be displayed in the first message. And the first message is displayed in the first session.

Abstract: In one embodiment, the present invention provides methods of modulating the deacetylase activity of SIRT1 in one or more cell by modifying the binding affinity of lamin A to SIRT1 via one or more interaction modifying compound. In another embodiment, the present invention provides methods of screening SIRT1-activating/inhibiting compounds based on the interaction between lamin A and SIRT1 proteins and SIRT1-activating property of lamin A. In another embodiment, the present invention provides uses of SIRT1-activating compounds to treat patient(s) suffering from metabolic and/or aging-related degenerative diseases, and uses of SIRT1-inhibiting compounds to treat human malignancies.

Abstract: In one embodiment, the present invention provides methods of modulating the deacetylase activity of SIRT1 in one or more cell by modifying the binding affinity of lamin A to SIRT1 via one or more interaction modifying compound. In another embodiment, the present invention provides methods of screening SIRT1-activating/inhibiting compounds based on the interaction between lamin A and SIRT1 proteins and SIRT1-activating property of lamin A. In another embodiment, the present invention provides uses of SIRT1-activating compounds to treat patient(s) suffering from metabolic and/or aging-related degenerative diseases, and uses of SIRT1-inhibiting compounds to treat human malignancies.

Abstract: This invention involves fabric-supported chitosan modified temperature responsive PNIPAAm/PU hydrogel and the use thereof in preparation of facial mask. The merit of this invention is the hydrogel formed can reversibly swell and deswell near body temperature; the incorporation of PU can suppress the syneresis of PNIPAAm at an elevated temperature; Grafting of PNIPAAm and PU onto the surface of cellulose fabrics can enhance the mechanical strength of hydrogel; Coupling of chitosan to the surface of hydrogel can not only improve the handle and skin affinity, but also render the facial mask antibacterial; The hydrogel is capable of loading a variety of nutrients (or other functional components), which can release at body temperature; the hydrogel facial mask can be reusable with repeated rinsing.

Abstract: This invention involves fabric-supported chitosan modified temperature responsive PNIPAAm/PU hydrogel and the use thereof in preparation of facial mask. The merit of this invention is the hydrogel formed can reversibly swell and deswell near body temperature; the incorporation of PU can suppress the syneresis of PNIPAAm at an elevated temperature; Grafting of PNIPAAm and PU onto the surface of cellulose fabrics can enhance the mechanical strength of hydrogel; Coupling of chitosan to the surface of hydrogel can not only improve the handle and skin affinity, but also render the facial mask antibacterial; The hydrogel is capable of loading a variety of nutrients(or other functional components), which can release at body temperature; the hydrogel facial mask can be reusable with repeated rinsing.

Abstract: The application disclosed a cell proliferation factor-Fwa267 polypeptide and the polynucleotide encoding the polypeptide and a process for producing the polypeptide by recombinant method, the antibody and antagonist against the polypeptide and a composition comprising Fwa267 polypeptide and its usage in the treatment of angiocardiopathy and cancer are also disclosed. The application further disclosed a diagnostic method by detecting the mutation in the nucleic acid sequence encoding Fwa 267 or the amount of Fwa267 in the sample or the changes of autoantibody of Fwa267 gene product. The cell proliferation factor of the present application is of human resource.

Abstract: The present invention relates to a polypeptide of the inflammatory inhibition factor Fwa116 and the polynucleotides encoding thereof. The present invention also relates to the method of producing polypeptide Fwa116 by recombinant technology and the antibody against it and an antagonist. The present invention also discloses pharmaceutical compositions containing the polypeptide Fwa116 and the use of the polypeptide in treating cardiovascular inflammatory arterosclerosis such as cerebral apoplexy, coronary heart disease, angina pectoris, myocardial infarction and controlling tumors. The present invention also provides the diagnosing and measuring method by detecting the mutation of nucleic acid sequence encoding Fwa116 or the content of the polypeptide Fwa116 and changes in levels of the auto-antibody of the gene product of Fwa116. The present inflammatory inhibition factor is human-derived.